Monoclonal antibody developerNeoRx of Seattle has signed an agreement with catheter maker Cordisof Miami in which Cordis will supply its Micro-Infusion Catheter(MIC) for use with NeoRx's Biostent anti-restenosis product underdevelopment. The MIC will be
Monoclonal antibody developerNeoRx of Seattle has signed an agreement with catheter maker Cordisof Miami in which Cordis will supply its Micro-Infusion Catheter(MIC) for use with NeoRx's Biostent anti-restenosis product underdevelopment. The MIC will be used to deliver Biostent immediatelyafter balloon angioplasty.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.